Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5668076 | 0.99 | MARS1 (0.59) | MARS1 | |
| Hydrochloric Acid SCHEMBL5669755 | 0.97 | MARS1 (0.58) | MARS1 | |
| Hydrochloric Acid SCHEMBL7992242 | 0.93 | MARS1 (0.57) | MARS1 | |
| Hydrochloric Acid SCHEMBL7817647 | 0.92 | MARS1 (0.56) | MARS1 | |
| Hydrochloric Acid SCHEMBL7995914 | 0.88 | MARS1 (0.54) | MARS1 | |
| SCHEMBL10070268 | 0.83 | CTSV (0.58) | MARS1 | |
| SCHEMBL5669207 | 0.76 | MARS1 (0.76) | MARS1 | |
| SCHEMBL5669892 | 0.76 | MARS1 (0.74) | MARS1 | |
| SCHEMBL14108051 | 0.75 | GAA (0.55) | MARS1 | |
| SCHEMBL7817860 | 0.75 | MARS1 (0.74) | MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1619947-A4 | ANTIBACTERIAL METHODS AND COMPOSITIONS | REPLIDYNE INC (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1619947-A2 | ANTIBACTERIAL METHODS AND COMPOSITIONS | Replidyne, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1603881-A2 | SUBSTITUTED THIOPHENES WITH ANTIBACTERIAL ACTIVITY | Replidyne, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005009336-A9 | ANTIBACTERIAL METHODS AND COMPOSITIONS | REPLIDYNE INC (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005009336-A2 | ANTIBACTERIAL METHODS AND COMPOSITIONS | REPLIDYNE, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040224981-A1 | Antibacterial methods and compositions | REPLIDYNE, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004078119-A2 | SUBSTITUTED THIOPHENES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224981-A1 | Antibacterial methods and compositions | AARS1, NOP2, NSUN3 | MARS1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.